Results 181 to 190 of about 19,639 (215)

Antiphospholipid antibody syndrome

Hematology, 2009
Abstract The antiphospholipid antibody syndrome (APS) is defined by the persistent presence of antiphospholipid antibodies in patients with recurrent venous or arterial thromboembolism or pregnancy morbidity. Anti-thrombotic therapy is the mainstay of treatment given the high risk of recurrent thromboembolism that characterizes this ...
openaire   +2 more sources

Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome

Lupus, 2009
The antiphospholipid antibodies included as laboratory criteria of the antiphospholipid syndrome (APS) are antibodies reacting with anionic phospholipids – anticardiolipin antibodies and lupus anticoagulant – and with β 2 -glycoprotein I.
M, Sanmarco, M-C, Boffa
openaire   +2 more sources

The geoepidemiology of the antiphospholipid antibody syndrome

Autoimmunity Reviews, 2010
Antiphospholipid antibodies (aPL) can be detected by functional (lupus anticoagulant) and/or by solid phase assays (anti-cardiolipin and anti-beta2 glycoprotein I). Although detectable in 1-5% of asymptomatic apparently healthy subjects, persistent aPL are significantly associated with recurrent arterial/venous thrombosis and with pregnancy morbidity ...
Martina Biggioggero, Pier Luigi Meroni
exaly   +3 more sources

Pediatric Antiphospholipid Antibodies and Antiphospholipid Syndrome

Seminars in Thrombosis and Hemostasis, 2008
Antiphospholipid syndrome (APS) can occur in children, like adults, with the same diverse spectrum of thrombotic sites but predominately with deep vein thrombosis and stroke. In contrast with adults, however, transient nonthrombogenic antiphospholipid (aPL) antibodies are seen more commonly, usually after childhood infections.
openaire   +2 more sources

A Review of Antiphospholipid Antibody Syndrome

Journal of the American Academy of Nurse Practitioners, 2001
PurposeTo review the pathophysiology, clinical presen‐tation, and management options for antiphos‐pholipid antibody syndrome (APS), a poten‐tially life‐threatening coagulation disorder.Data SourcesSelected scientific literature, consensus guide‐lines, and expert opinion.ConclusionsClinical features that should alert the clinician to consider APS ...
Lorna Schumann, Jill Olmstead
openaire   +2 more sources

The HELLP syndrome, antiphospholipid antibodies, and syndromes

Clinical Rheumatology, 2007
A recent publication in this journal has drawn attention to the association of HELLP syndrome with antiphospholipid antibodies (aPL) accompanied by a 20210A mutation of the prothrombin gene, resulting in bilateral deep vein thromboses after termination of the pregnancy [1]. The association of hemolysis-elevated liver enzymes and thrombocytopenia, known
Ronald A, Asherson, Claudio, Galarza-Maldonado, Jose, Sanin-Blair   +2 more
openaire   +2 more sources

Antiphospholipid antibodies and antiphospholipid syndrome

Ugeskrift for Læger
Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular ...
Rasmus Søgaard Hansen, Julie Brogaard Larsen, Pernille Just Vinholt, Anne Voss, Anders Abildgaard   +4 more
openaire   +1 more source

The Antiphospholipid Antibody Syndrome: An Overview

Journal of Obstetric, Gynecologic & Neonatal Nursing, 1997
The antiphospholipid antibody syndrome is characterized by the presence of maternal anticardiolipin antibodies and/or the lupus anticoagulant in association with recurrent pregnancy loss, thrombotic events, and/or thrombocytopenia. This disorder occurs rarely, but pregnant patients with antiphospholipid antibodies are at risk for adverse maternal and ...
J L, Atterbury, M B, Munn, L J, Groome, J A, Yarnell   +3 more
openaire   +2 more sources

Antiphospholipid Antibody Syndrome: Treatment

Lupus, 1996
Of the many clinical manifestations seen in the antiphospholipid antibody syndrome (APAS), two deserve major therapeutic consideration: recurrent fetal loss and vascular thromboses. Treatment of these two major complications remain empirical, although recent studies appear to indicate the beneficial use of multiple therapeutic options including low ...
openaire   +2 more sources

Pathogenesis of the Antiphospholipid Antibody Syndrome

Lupus, 1996
Endothelial and/or platelet activation likely initiates thrombus formation. Whether antiphospholipid antibody (aPL) is an activator, a toxic response, or a protective response is not clear, nor is it certain whether aPL is germ-line encoded or antigen-driven. The pregnancy model is particularly informative.
openaire   +2 more sources